Replimune Group, Inc. (REPL) bonds
REPLNasdaqBiological Products, (No Diagnostic Substances)Fiscal year ends March 31
Financials through Q2 FY2027, quarter ended Sep 30, 2026Last filing: 10-Q/A on Nov 6, 2026Score 1/30
$21.78−1.50 (-6.44%)
Close on Nov 11, 2026Market cap $2.06BP/E –Yield –
Debt
Borrowings on the balance sheet, Sep 30, 2026
Total debt
$99.77M
Long-term debt
Net debt
-$208.07M
After $307.83M of cash
Implied interest rate
10.48%
FY2026 interest ÷ average debt
Interest coverage
-47.1×
FY2026 operating income ÷ interest
Total debt by fiscal year
Long-term plus current debt, USD
Notes and loans outstanding
As tagged in Replimune's 10-Q for the period ended Sep 30, 2026
Replimune's filings do not break debt down by note
The debt footnote in the annual report has no machine-readable detail for individual notes, so coupons and maturities cannot be listed.
Credit facilities
Revolving credit lines and other committed borrowing capacity
| Facility | Size | Drawn |
|---|---|---|
| Term Loan Facility | $200.00M | $97.88M |
| Term Loan Facility, Tranche Five | $25.00M | – |
| Term Loan Facility, Tranche Four | $15.00M | – |
| Term Loan Facility, Tranche One | $30.00M | – |
| Term Loan Facility, Tranche One and Two | $60.00M | – |
| Term Loan Facility, Tranche Three | $35.00M | – |
| Term Loan Facility, Tranche Two | $15.00M | – |
See a number that looks wrong?